Home > Insider Trading > Filing (0001415889-24-010232)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	Pharmaceutical Preparations (2834)	811523849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1805097	D. Rahul Ballal	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-04-01	94	$12.60	22,435	No	4	M	Direct
Common Stock	Acquisiton	2024-04-01	3,143	$5.52	25,578	No	4	M	Direct
Common Stock	Disposition	2024-04-01	3,237	$19.08	22,341	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-04-01	94	$0.00	94	$12.60
Common Stock	Stock Option (right to buy)	Disposition	2024-04-01	3,143	$0.00	3,143	$5.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
65,905		2028-10-19	No	4	M	Direct
16,428		2032-01-28	No	4	M	Direct

Footnotes

The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
This transaction was executed in multiple trades at prices ranging from $19.00 to $19.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
All of the shares subject to this option are fully vested and exercisable as of the date hereof.
The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split").
The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.